Immunovant, Inc.
Financials
Valuation Metrics
Immunovant, Inc.'s Market Cap is $5.83B. At end of 2025 it was $4.61B. Ranked #1197 of 3,115 in US market (top 38%), #397 of 1,472 on NASDAQ (top 27%), #68 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.83B | US#1,197/3,115 Sec#68/265 |
| Revenue | $7M | US#2,815/3,115 Sec#173/265 |
| Net Income | $-538M | US—/3,115 Sec—/265 |
| Total Assets | $852M | US#2,537/3,115 Sec#114/265 |
| Net Assets | $735M | US#1,968/3,115 Sec#82/265 |
| Employees | 315 | US#2,397/3,115 Sec#107/265 |
| Value | ||
| P/B | 7.93x | US#2,535/3,115 Sec#183/265 |
| P/S | 822.10x | US#2,986/3,115 Sec#198/265 |
| FCF Yield | -7.10% | US—/3,115 Sec—/265 |
| Profitability | ||
| ROE | -73.19% | US#2,751/3,115 Sec#191/265 |
| ROA | -63.13% | US#3,018/3,115 Sec#233/265 |
| Op. Margin | -7877.46% | US#2,842/3,115 Sec#182/265 |
| Financial Health | ||
| Debt Ratio | 15.92% | US#177/3,115 Sec#69/265 |
| Total Debt | $0.00 | US—/3,115 Sec—/265 |
| FCF | $-414M | US#2,883/3,115 Sec#246/265 |
| Cash | $798M | US#790/3,115 Sec#38/265 |
| Current Ratio | 7.27x | US#340/3,115 Sec#105/265 |
| Performance | ||
| 1Y Return | 15.11% | US#758/3,115 Sec#90/265 |
| 1M Return | -15.50% | US#2,679/3,115 Sec#206/265 |
| From 52W High | -37.45% | US#2,202/3,115 Sec#153/265 |
| 1Y MDD | -40.55% | US#1,956/3,115 Sec#124/265 |
| Trading | ||
| Volume | 1,242,010 shares | US#1,331/3,115 Sec#135/265 |
| Trading Value | $36M | US#1,561/3,115 Sec#116/265 |
| Per Share | ||
| EPS | $-2.62 | US—/3,115 Sec—/265 |
| BPS | $3.58 | US#2,404/3,115 Sec#148/265 |
Company Info
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.